Page 349 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 16 Supportive Care for the Cancer Patient 327

E and leukotriene B production by a human breast cancer cell line 364. Hayes KC: Nutritional problems in cats: taurine deficiency and
(MDA-MB-231), Oncology 52:458–464, 1995. vitamin A excess, Can Vet J 23:2–5, 1982.
343. Hawcroft G, Loadman PM, Belluzzi A, et al.: Effect of eicosapen- 365. Rassnick KM, Muindi JR, Johnson CS, et al.: Oral bioavailability
VetBooks.ir taenoic acid on E-type prostaglandin synthesis and EP4 receptor of DN101, a concentrated formulation of calcitriol, in tumor-
bearing dogs, Cancer Chemother Pharmacol 67:165–171, 2011.
signaling in human colorectal cancer cells, Neoplasia 12:618–627,
2010.
344. Hayashi T, Nishiyama K, Shirahama T: Inhibition of 5-lipoxygen- 366. Malone EK, Rassnick KM, Wakshlag JJ, et al.: Calcitriol enhances
mast cell tumour chemotherapy and receptor tyrosine kinase
ase pathway suppresses the growth of bladder cancer cells, Int J Urol inhibitor activity in-vitro and has single agent activity against spon-
13:1086–1091, 2006. taneously occurring canine mast cell tumours, Vet Comp Oncol
345. Schley PD, Brindley DN, Field CJ: (n-3) PUFA alter raft lipid 8:209–220, 2010.
composition and decrease epidermal growth factor receptor levels 367. Nelson MA, Porterfield BW, Jacobs ET, et al.: Selenium and pros-
in lipid rafts of human breast cancer cells, J Nutr 137:548–553, tate cancer prevention, Semin Urol Oncol 17:91–96, 1999.
2007. 368. Reid ME, Duffield-Lillico AJ, Garland L, et al.: Selenium sup-
346. Furstenberger G, Krieg P, Muller-Decker K, et al.: What are cyclo- plementation and lung cancer incidence: an update of the nutri-
oxygenases and lipoxygenases doing in the driver’s seat of carcino- tional prevention of cancer trial, Cancer Epidemiol Biomarkers Prev
genesis, Int J Cancer 119:2247–2254, 2006. 11:1285–1291, 2002.
347. Mohammed SI, Bennett PF, Craig BA, et al.: Effects of the cyclo- 369. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al.: Selenium supple-
oxygenase inhibitor, piroxicam, on tumor response, apoptosis and mentation, baseline plasma selenium status and incidence of pros-
angiogenesis in a canine model of human invasive urinary bladder tate cancer: an analysis of the complete treatment period of the
cancer, Cancer Res 62:356–358, 2002. Nutritional Prevention of Cancer Trial, BJU Int 91:608–612, 2003.
348. McMillan SK, Boria P, Moore GE, et al.: Antitumor effects of dera- 370. Clark LC, Comb Jr GF, Turnbull BW, et al.: Effects of selenium
coxib treatment in 26 dogs with transitional cell carcinoma of the supplementation for cancer prevention in patients with carcinoma
urinary bladder, J Am Vet Med Assoc 239:1084–1089, 2011. of the skin. A randomized controlled trial. Nutritional Prevention
349. Hanahan D, Weinberg RA: Hallmarks of cancer: the next genera- of Cancer Study Group, J Am Med Aassoc 276:1957–1963, 1996.
tion, Cell 144:646–674, 2011. 371. Xiao SD, Meng XJ, Shi Y, et al.: Interventional study of high
350. Weylandt KH, Krause LF, Gomolka B, et al.: Suppressed liver dose folic acid in gastric carcinogenesis in beagles, Gut 50:61–64,
tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is 2002.
associated with increased omega-3 derived lipid mediators and 372. Jhaveri MS, Wagner C, Trepel JB: Impacts of extracellular folate
reduced TNF-α, Carcinogenesis 32:897–903, 2011. levels on global gene expression, Mol Pharmacol 60:1288–1295,
351. Endres S, Ghorbani R, Kelley VE, et al.: The Effect of dietary sup- 2001.
plementation with n-3 polyunsaturated fatty acids on the synthesis 373. Friso S, Choi SW: The potential cocarcinogenic effect of vitamin
of interleukin-1 and tumor necrosis factor by mononuclear cells, B12 deficiency, Clin Chem Lab Med 43:1158–1163, 2005.
N Engl J Med 320:265–271, 1989. 374. Lana SE, Kogan LR, Crump KA, et al.: The use of complementary
352. Purasiri P, Murray A, Richardson S, et al.: Modulation of cytokine and alternative therapies in dogs and cats with cancer, J Am An Hosp
production in vivo by dietary essential fatty acids in patients with Assoc 42:361–365, 2006.
colorectal cancer, Clin Sci 87:711–717, 1994. 375. Rajagopaul S, Parr JM, Woods JP, et al.: Owners’ attitudes and
353. Dewey A, Baughan C, Dean T, et al.: Eicosapentaenoic acid (EPA, practices regarding nutrition of dogs diagnosed with cancer pre-
an omega-3 fatty acid from fish oils) for the treatment of cancer senting at a referral oncology service in Ontario, Canada, J Small
cachexia, Cochrane Database Syst Rev 24:CD004597, 2007. Anim Pract 57:484–490, 2016.
354. Saker KE, Eddy AL, Thatcher CD, et al.: Manipulation of dietary 376. Seifried HE, McDonald SS, Anderson DE, et al.: The antioxidant
(n-6) and (n-3) fatty acids alters platelet function in cats, J Nutr conundrum in cancer, Cancer Res 63:4295–4298, 2003.
128:2645s–2647s, 1998. 377. Szczubial M, Kankofer M, Lopuszynski W, et al.: Oxidative stress
355. Freeman LM, Rush JE, Kehayias JJ, et al.: Nutritional alterations parameters in bitches with mammary gland tumors, J Vet Med
and the effect of fish oil supplementation in dogs with heart failure, 51:336–340, 2004.
J Vet Intern Med 12:440–448, 1998. 378. Winter JL, Barber LG, Freeman TM, et al.: Antioxidant status and
356. Freeman LM, Rush JE: Cardiovascular diseases: nutritional modu- biomarkers of oxidative stress in dogs with lymphoma, J Vet Int
lation. In Pibot P, Ellliot D, Biourge V, editors: Encyclopedia of Med 23:311–316, 2009.
canine clinical nutrition, ed 1, Paris, 2006, Aniwa SAS, pp 316– 379. Chandhok D, Saha T: Redox regulation in cancer: a double-edged
347. sword with therapeutic potential, Oxid Med Cell Longev 3:23–34,
357. Kikawa KD, Herrick JS, Tateo RE, et al.: Induced oxidative stress 2010.
and cell death in the A549 lung adenocarcinoma cell line by ion- 380. Zhao CR, Gao ZH, Qu XJ: Nrf2-ARE signaling pathway and
izing radiation is enhanced by supplementation with docosahexae- natural products for cancer chemoprevention, Cancer Epidemiol
noic acid, Nutr Cancer 62:1017–1024, 2010. 34:523–533, 2010.
358. Hopewell JW, van den Aardweg GJ, et al.: Amelioration of both 381. Crozier A, Jaganath IB, Clifford MN: Dietary phenolics: chemistry,
early and late radiation-induced damage to pig skin by essential bioavailability and the effects on health, Nat Prod Rep 26:1001–
fatty acids, Int J Radiat Oncol Biol Phys 30:1119–1125, 1994. 1043, 2009.
359. Fulan H, Changxing J, Baina WY, et al.: Retinol, vitamins A, C, 382. Khan N, Afaq F, Mukhtar H: Cancer chemoprevention through
and E and breast cancer risk: a meta-analysis and meta-regression, dietary antioxidants: progress and promise, Antioxidants Redox Sig-
Cancer Causes Control 22:1383–1396, 2011. nal 10:1–36, 2008.
360. Arain MA, Abdul Qadeer A: Systematic review on “vitamin E and 383. Shanmugam MK, Kannaiyan R, Sethi G: Targeting cell signaling
prevention of colorectal cancer”, Pak J Pharm Sci 23:125–130, and apoptotic pathways by dietary agents: role in the prevention
2010. and treatment of cancer, Nutr Cancer 63:161–173, 2011.
361. Paik J, Blaner WS, Sommer KM, et al.: Retinoids, retinoic acid 384. Wakshlag JJ, Balkman CA, Morgan SK, et al.: Evaluation of the
receptors, and breast cancer, Cancer Invest 21:304–312, 2003. protective effects of all-trans-astaxanthin on canine osteosarcoma
362. Tang XH, Gudas LJ: Retinoids, retinoic acid receptors, and cancer, cell lines, Am J Vet Res 71:89–96, 2010.
Annu Rev Pathol 6:345–364, 2011. 385. Wakshlag JJ, Balkman CE: Effects of lycopene on proliferation and
363. Bushue N, Wan YJ: Retinoid pathway and cancer therapeutics, Adv death of canine osteosarcoma cells, Am J Vet Res 71:1362–1370,
Drug Deliv Rev 62:1285–1298, 2010. 2010.